ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Diagnostic Biomarker Candidates Including NT5DC2 for Human Uterine Mesenchymal Tumors

Journal: International Journal of Trend in Scientific Research and Development (Vol.5, No. 3)

Publication Date:

Authors : ;

Page : 60-64

Keywords : leiomyosarcoma; leiomyoma; mesenchymal tumor; LMP2/ß1i;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Unfortunately, uterine leiomyosarcoma still has a poor prognosis. The National Cancer Institute reported that the median overall survival mOS at stage I to stage IV of leiomyosarcoma was 31 months. Norwegian reports show that mOS of uterine leiomyosarcoma is as poor as eight years at stage I, four years at stage II, two years at stage III, and one year at stage IV. Preoperative diagnosis of uterine leiomyosarcoma is difficult in clinical practice. Treated as uterine leiomyoma , however, tumors are often differentially diagnosed from uterine leiomyosarcoma by pathological diagnosis with hysterectomy or myomectomy. Histopathological diagnosis may result in a diagnosis of smooth muscle tumor of unmalignant potential STUMP , and leiomyoma with bizarre nuclei that cannot be declared as malignant or benign. In about half of stage I patients, uterine leiomyosarcoma recurs. However, at present, no anticancer drug that has been shown to be effective in preventing postoperative recurrence has not been established. For this reason, we monitor patients without postoperative treatment, and start clinical treatment when recurrence is confirmed. Uterine leiomyomas, which occur in about 70 of women aged 40 and over in Japan and overseas, are benign tumors, but are extremely difficult to distinguish from uterine leiomyosarcoma. Although progress in diagnostic imaging such as Magnetic Resonance Imaging MRI and Positron Emission Tomography Computed Tomography PET CT is remarkable, uterine leiomyosarcoma is difficult to distinguish from other uterine mesenchymal tumors. No differential biomarker has been identified for uterine other uterine mesenchymal tumors and uterine leiomyosarcoma in surgical pathological diagnosis or clinical examination. This review describes the current diagnosis and treatment for uterine sarcoma, including new trends in the search for biomarker candidates for uterine leiomyosarcoma. Takuma Hayashi | Kenji Sano | Tomoyuki Ichimura | Susumu Tonegawa | Nobuo Yaegashi | Ikuo Konishi "Diagnostic Biomarker Candidates Including NT5DC2 for Human Uterine Mesenchymal Tumors" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-3 , April 2021, URL: https://www.ijtsrd.com/papers/ijtsrd38686.pdf Paper URL: https://www.ijtsrd.com/medicine/other/38686/diagnostic-biomarker-candidates-including-nt5dc2-for-human-uterine-mesenchymal-tumors/takuma-hayashi

Last modified: 2021-06-09 14:13:06